BCM-95® (CURCUGREEN®), 07 Aug 2021

Mahsa Adibian | Homa Hodaei | Omid Nikpayam | Golbon Sohrab | Azita Hekmatdoost | Mehdi Hedayati

DOI: 10.1002/ptr.6328 Received: 27 August 2018 Revised: 13 January 2019 Accepted: 3 February 2019

Introduction: Diabetes mellitus is one of the most common and important metabolic diseases in human. Curcumin, which is a natural polyphenol found in turmeric, can be used in treatment of diabetes complications for its antidiabetic, anti‐inflammatory, and antioxidant properties. In this double‐blind randomized clinical trial, 44 patients with Type2 diabetes randomly assigned to curcumin or placebo group.

Method: Patients consumed either 1,500‐mg curcumin or placebo daily for 10 weeks. Anthropometric measurements were measured at baseline and at the end of the study. Serum concentrations of triglyceride (TG), total cholesterol, high‐density lipoprotein cholesterol, low‐density lipoprotein cholesterol, high‐sensitivity C‐reactive protein, and adiponectin were determined after 12‐hr fasting at the beginning and end of study. The mean serum level of TG decreased in curcumin group compared with baseline (109 ± 36 vs. 124 ± 36; p < 0.05). At the end of study, the mean concentration of high‐sensitivity C‐reactive protein decreased in the curcumin group compared to the control (2.9 ± 2.9 vs. 3.4 ± 4.2; p < 0.05). The mean serum concentration of adiponectin increased (64 ± 3 vs. 63 ± 4; p < 0.05) in the treatment group compared with the placebo at the end of the study.

Result: The results of the current study indicate that Curcumin consumption may reduce diabetes complications through decreasing TG level as well as indicators of inflammation.

(https://onlinelibrary.wiley.com/doi/10.1002/ptr.6328)